Coherus Oncology (CHRS) Share-based Compensation (2013 - 2026)
Coherus Oncology (CHRS) posted Share-based Compensation of $2.4 million for Q1 2026, up 16935.71% sequentially from $14000.0 in Q4 2025, and up 881.48% YoY from $243000.0 in Q1 2025.
Coherus Oncology (CHRS) Share-based Compensation (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Share-based Compensation for 14 years, with the latest figure at $2.4 million in Q1 2026.
- Quarterly Share-based Compensation rose 881.48% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (down 61.86% YoY) and the FY2025 annual result came in at $10.7 million, down 56.5% from the prior year.
- Share-based Compensation grew to $2.4 million in Q1 2026 per CHRS's latest filing, from $14000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $10.1 million in Q2 2023 and troughed at -$35.3 million in Q4 2022.
- A 5-year average of $410176.5 and a median of $394000.0 in 2024 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 2046.47% in 2022, down 422.19% in 2022.
- Over 5 years, Share-based Compensation stood at -$35.3 million in 2022, then jumped by 101.03% to $365000.0 in 2023, then tumbled by 390.14% to -$1.1 million in 2024, then soared by 101.32% to $14000.0 in 2025, then jumped by 16935.71% to $2.4 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.4 million, $14000.0, and $19000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.58 Mn |
| Jun 30, 2026 | 2.58 Mn |
| Mar 31, 2026 | 2.39 Mn |
| Mar 31, 2026 | 2.39 Mn |
| Dec 31, 2025 | 14,000.00 |
| Dec 31, 2025 | 14,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Mar 31, 2025 | 243,000.00 |
| Mar 31, 2025 | 243,000.00 |
| Dec 31, 2024 | -1.06 Mn |
| Dec 31, 2024 | -1.06 Mn |
| Sep 30, 2024 | 6.87 Mn |
| Sep 30, 2024 | 6.87 Mn |
| Jun 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 394,000.00 |
| Mar 31, 2024 | 394,000.00 |